Skip to content

A longitudinal non-invasive study of changes in urinary bladder contractility secondary to benign prostatic hyperplasia.

A longitudinal non-invasive study of changes in urinary bladder contractility secondary to benign prostatic hyperplasia.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN46624580
Enrollment
1020
Registered
2005-12-20
Start date
2001-11-01
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia (BPH) Urological and Genital Diseases Benign Prostatic Hyperplasia (BPH)

Interventions

Sponsors

Erasmus Medical Centre (Netherlands)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Men aged 38 - 77 years 2. Mentally and physically able to complete a voiding diary and to visit the outpatient clinic 3. Written informed consent to participate in the trial

Exclusion criteria

Exclusion criteria: 1. Unable to urinate in a standing position 2. Previous lower urinary tract surgery 3. Congenital disease of the lower urinary tract 4. Use of medication or other interventions for lower urinary tract symptoms 5. Other diseases that could alter urinary function (e.g., Parkinsons, Cerebrovascular Accident [CVA], Diabetes Mellitus [DM], kidney failure, bladder/prostate cancer, current urinary tract infection) 6. Heart failure 7. Voiding pattern at first visit incompatible with measurement technique, e.g., flow rate too low (less than 6 ml/s), interrupted voiding, straining 8. Mentally or physically unable to complete a voiding diary and to visit the outpatient clinic 9. Use anticoagulants

Design outcomes

Primary

MeasureTime frame
The study is observational, there is no endpoint.

Secondary

MeasureTime frame
No secondary outcome measures

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026